Alumis (ALMS) Net Income towards Common Stockholders (2023 - 2025)
Alumis (ALMS) reported Net Income towards Common Stockholders of -$93.0 million for Q4 2025, up 1.89% year-over-year from -$91.2 million in Q4 2024, and up 16.06% quarter-over-quarter from -$110.8 million in Q3 2025.
Alumis (ALMS) Net Income towards Common Stockholders (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$93.0 million in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$93.0 million, up 1.89% year-over-year; the trailing twelve-month figure through Dec 2025 was -$245.9 million (up 15.77% YoY), and the FY2025 annual result was -$243.3 million, up 17.3% from the prior year.
- Net Income towards Common Stockholders grew to -$93.0 million in Q4 2025 per ALMS's latest filing, from -$110.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $59.3 million in Q2 2025 and troughed at -$110.8 million in Q3 2025.
- A 3-year average of -$59.9 million and a median of -$56.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 136.12% in 2024, then jumped 204.98% in 2025.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$40.1 million in 2023, then tumbled by 136.12% to -$94.8 million in 2024, then gained by 1.89% to -$93.0 million in 2025.
- Business Quant data shows ALMS's Net Income towards Common Stockholders at -$93.0 million in Q4 2025, -$110.8 million in Q3 2025, and $59.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | -92.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -92.97 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | -101.53 Mn |
| Dec 31, 2024 | -94.76 Mn |
| Sep 30, 2024 | -93.12 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -47.59 Mn |
| Dec 31, 2023 | -40.13 Mn |
| Sep 30, 2023 | -43.76 Mn |
| Jun 30, 2023 | -36.71 Mn |